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Should we screen for cirrhosis?
Recent guidelines are right to recommend screening high risk patients for liver cirrhosis, say Mark
Hudson and Nick Sheron. But Ian Rowe and Gideon Hirschfield worry about the lack of a suitable
screening test
Mark Hudson consultant hepatologist 1, Nick Sheron head of clinical hepatology 2, Ian A Rowe
university academic fellow 3, Gideon M Hirschfield professor 4
1Freeman Hospital, Newcastle upon Tyne, UK; 2Southampton General Hospital, University of Southampton, UK; 3Leeds Institute for Data Analytics,
University of Leeds, UK ; 4Centre for Liver Research, NIHR Biomedical Research Centre, University of Birmingham, Birmingham, UK
Yes— Mark Hudson and Nick Sheron
Liver disease is the second leading cause of potential years of
working life lost in England and Wales (72 684), after ischaemic
heart disease (77 432). But although years lost from ischaemic
heart disease have fallen by a factor of four since 1979, those
from liver disease years have increased threefold and are still
increasing.1 The increase is in constrast to the trend in
Mediterranean regions of Europe (France, Italy, Spain, Portugal,
and Greece), which historically had the highest cirrhosis
mortality but have seen significant declines. Reduction in
alcohol consumption, hepatitis B vaccination and reduced
hepatitis C transmission have contributed to this decrease.2
Liver disease will probably overtake heart disease to become
the commonest cause of death in working age people in England
and Wales in the next year or so. Only a third of patients
admitted to hospital with liver disease will recover. There is no
indication that things are improving, and there are at least two
reasons for this.
Firstly, therapeutic options for the commonest causes of liver
disease, alcohol and obesity, are limited. Secondly, liver disease
develops without signs or symptoms, and many patients present
with often fatal complications of late stage cirrhosis. Data
presented in the Lancet commission report in 2014 indicated
that 75% of 5000 patients admitted as an emergency for liver
disease in Southampton had not been previously referred to a
liver or gastroenterology clinic, suggesting that the liver disease
had not been detected beforehand.3
Detection in primary care
Liver disease takes between 10 and 50 years to progress through
fibrosis to cirrhosis, portal hypertension, liver failure, and liver
cancer. It ought to be possible to detect patients with cirrhosis
in primary care, but there diagnosis relies on tests for the enzyme
alanine transaminase (ALT), and ALT concentrations are
unrelated to stage of liver fibrosis; a recent systematic review
found that 90% of patients with cirrhosis would not have been
identified using standard liver tests.4
The answer is to go upstream. A 30 year upward trend in
mortality from liver disease in the UK was reversed by the 2008
budget, which increased alcohol duty; however, the policy was
abolished in 2013, at a cost of £3.5bn in lost duty, and since
then liver deaths have been increasing again.5 Similarly, the
solution for clinical hepatology is to go upstream; the
technologies to identify early liver disease exist and are
supported by the National Institute for Health and Care
Excellence (NICE).
NICE guidelines
Recent guidelines on cirrhosis from NICE recommend that men
and women drinking alcohol at potentially harmful levels—more
than 50 and 35 units a week, respectively—be offered transient
elastography (fibroscan) to exclude cirrhosis.6 This equates to
about 2.25 million people in England and Wales. Reports
suggest elastography is an efficient technique to exclude the
diagnosis of cirrhosis whatever the cause. With a cut-off value
of 14.6 kPa, chosen to obtain a 95% specificity, positive and
negative predictive values for diagnosing cirrhosis are 74% and
96% respectively.7
Currently few GPs have access to this test so change is not going
to happen overnight. However, because the lifetime cost of
treating liver disease is between £50 000 and £120 000,8 this
approach is likely to be cost effective.
One important question remains: if we detect patients with
cirrhosis earlier, can we prevent progression of the disease?
There are already highly effective treatments for viral hepatitis
and autoimmune liver disease, and numerous compounds are
in advanced clinical trials for non-alcoholic fatty liver disease.9
About 40-50% of patients with alcohol related liver disease will
stop drinking after admission with cirrhosis,10 and evidence from
Correspondence to: M Hudson Mark.Hudson@nuth.nhs.uk, I A Rowe i.a.c.rowe@leeds.ac.uk
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2017;358:j3233 doi: 10.1136/bmj.j3233 (Published 2017 July 13) Page 1 of 3
Head to Head
HEAD TO HEAD
a feasibility study shows that a community diagnosis also
reduces hazardous drinking.11
We will need properly controlled trials, and these studies are in
preparation. However, the burden of liver disease is such that
doctors cannot simply sit in their ivory towers waiting for
patients with liver disease to come and find them.\
No— Ian Rowe and Gideon Hirschfield
Despite recent recommendations from NICE,6 12 insufficient
evidence supports a screening programme for cirrhosis.
Histologically definable cirrhosis is the culmination of many
liver injuries, some prevalent (alcohol, non-alcoholic fatty liver,
and viral) and others rare (genetic, autoimmune). Regardless of
cause, cirrhosis carries an increased risk of
complications—namely, liver failure, primary liver cancer
(hepatocellular carcinoma), and ultimately death.
As physicians in busy liver units we see complications of liver
disease every day, so conceptually, cirrhosis seems an attractive
target for screening to prevent an array of costly personal and
societal events. The rising burden of liver disease in the UK,
with a 400% rise in death rates since 1970, sweetens this appeal.3
But conceptual simplicity must not be confused with validated
justification.
For a successful screening programme the test used must be
simple, cheap, and, most importantly, accurate. Early
identification of disease is of benefit to patients only if there
are effective surveillance strategies or treatments that can be
implemented as a result. Any screening intervention must also
be cost effective.
Evidence is lacking
A focus on the largest group at risk, the three million people in
the UK estimated to be drinking alcohol hazardously,13 highlights
where evidence to support screening is lacking.
The test proposed to screen for cirrhosis—transient
elastography—is not widely available and would require huge
up-front investment to establish it in community settings. It has
also been shown to perform poorly in people suspected to have
alcohol related liver disease, with a false positive rate of 29%.14
Using this test to screen all hazardous drinkers would therefore
lead to many people being incorrectly labelled as having
cirrhosis.
For example, if one million hazardous drinkers were screened
and the true prevalence of cirrhosis among them is 10%, about
260 000 people would be falsely labelled as having
cirrhosis—more than double the true number.
These people would subsequently be subjected to unnecessary
surveillance interventions—including regular ultrasonography
for the early diagnosis of liver cancer and upper gastrointestinal
endoscopy for the detection of large oesophageal
varices—without any prospect of benefit and the risk of
complications. In addition, concerns raised about the
complications of cirrhosis, including the development of liver
cancer, may cause psychosocial harms.15
The most important action for a patient at risk of, or with,
alcohol related liver disease is to reduce their alcohol
consumption. This is recommended regardless of the result of
any screening test for cirrhosis because it not only prevents
progression of liver disease but protects the person from other
harms related to hazardous alcohol consumption.
Existing brief alcohol interventions have been proved effective
in reducing alcohol consumption.16 17 Whether they are enhanced
by a screening test for cirrhosis is unknown. Without this
evidence, it is more rational to identify people at risk of cirrhosis
and implement interventions known to improve their health.
Surveillance interventions for patients with cirrhosis are
associated with an uncertain benefit in terms of reducing
mortality from liver disease. Surveillance for the development
of liver cancer in particular is controversial since it is not
supported by randomised controlled trials.18 19
Opportunity costs
Finally, a screening programme for cirrhosis could worsen
population health when healthcare resources are limited.
Screening for cirrhosis in people who drink alcohol hazardously
is probably not cost effective at the £20 000 per quality adjusted
life year (QALY) threshold.6 The true cost effectiveness would
likely be even less because the modelling included unrealistically
positive estimates of long term abstinence rates after screening.20
At that level of cost effectiveness, and given the resource
constraints in the NHS, implementation of screening for cirrhosis
would inevitably lead to disinvestment in other, more effective
interventions, risking the overall health of the population.21
Treating the most common liver diseases requires a risk factor
based approach—using brief interventions to reduce alcohol
consumption and addressing obesity and metabolic risk factors
in people with non-alcoholic fatty liver disease—rather than a
specific diagnosis of cirrhosis.
Resources should be targeted at managing these risk factors as
well as investing in well designed trials that evaluate the clinical
and cost effectiveness of screening strategies employing more
widely available and accurate blood test based tools,22 starting
in people at risk of alcohol related liver disease. Currently,
though, the evidence does not support screening.
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